William Blair analyst Matt Phipps maintained a Buy rating on Agenus (AGEN – Research Report) on June 29. The company's shares closed last Friday at $1.96, close to its 52-week low of $1.25. According to TipRanks.com, Phipps ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.5% and a 39.5% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Chinook Therapeutics, and Tempest Therapeutics. The the analyst consensus on Agenus is currently a Moderate Buy rating.
https://www.tipranks.com/news/blurbs/william-blair-thinks-agenus-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Agenus Charts.
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Agenus Charts.